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Abstract: Optogenetics and photopharmacology provide spa-
tiotemporally precise control over protein interactions and
protein function in cells and animals. Optogenetic methods that
are sensitive to green light and can be used to break protein
complexes are not broadly available but would enable multi-
chromatic experiments with previously inaccessible biological
targets. Herein, we repurposed cobalamin (vitamin B12) bind-
ing domains of bacterial CarH transcription factors for green-
light-induced receptor dissociation. In cultured cells, we
observed oligomerization-induced cell signaling for the fibro-
blast growth factor receptor 1 fused to cobalamin-binding
domains in the dark that was rapidly eliminated upon
illumination. In zebrafish embryos expressing fusion receptors,
green light endowed control over aberrant fibroblast growth
factor signaling during development. Green-light-induced
domain dissociation and light-inactivated receptors will crit-
ically expand the optogenetic toolbox for control of biological
processes.
Optogenetic methods provide spatially and temporally
precise control over molecular processes, cellular signals,
and animal behavior by making use of microbial or plant
photoreceptor domains that are capable of light-controlled
inter- or intramolecular interactions. The currently available
domain repertoire allows for blue- or red-light-induced
formation of protein complexes;[1] light oxygen voltage
(LOV) sensing domains and phytochromes (PHYs) homodi-
merize,[2] PHYs and cryptochromes (CRYs) heterodimerize
with accessory proteins,[3] and CRYs also oligomerize.[4]
Furthermore, blue- or red-light-induced dissociation of
stable complexes that spontaneously form in the dark has
been observed in LOV domains in vitro[5] and for PHYs and
CRYs in yeast screens,[6] and has been implemented as
optogenetic tools using LOV domains and engineered
fluorescent proteins.[7] However, none of the currently used
photoreceptor domains are maximally responsive to green
light, which constitutes a notorious “blind spot” in optoge-
netic experiments (Figure 1a). Herein, we employ cobalamin
(vitamin B12) binding domains (CBDs) to mediate receptor
interaction in the dark that can be abolished by green light,
Figure 1. a) Chromophores of main photoreceptor classes (1: p-cou-
maric acid, 2: flavins, 3: retinal, 4: tetrapyrroles, 5: AdoCbl).
b) Domain structure of CarH with light-sensitive CBD and DNA
binding domain (DBD; HTH=helix-turn-helix motif), drawn to scale
for CarH of M. xanthus. c) In the dark, CBDs with bound AdoCbl
assemble into tetramers. Upon illumination, the 5’-deoxyadenosyl
group is cleaved, and the complex dissociates. d) Fluorescence inten-
sity of mV-tagged MxCBD, TtCBD, or FKBP expressed in HEK293 cells,
with non-transfected (n.t.) cells as negative control. e) Metabolic
activity of HEK293 cells expressing mV-MxCBD, mV-TtCBD, or mV-
FKBP and a 5% DMSO treated control with reduced viability. Mean
values : SEM for three independent experiments each performed in
triplicate are given in (d) and (e).
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and apply these domains to regulate signaling pathways in
human cells and development in zebrafish embryos.
Functional, photochemical, and structural information on
the CBDs of CarH of Myxococcus xanthus and Thermus
thermophilus and the related LitR of Streptomyces coelicolor
and Bacillus megaterium has emerged in recent years, and
these proteins represent an active area of photobiology
research (Figure 1b, c).[8] These transcription factors act as
light-sensitive repressors of carotenoid synthesis. Their rela-
tively small CBDs (ca. 200 amino acids in length) mediate the
assembly of dimers of dimers in the dark; these dissociate into
monomers upon green-light irradiation after photolytic
cleavage of the 5’-deoxyadenosylcobalamin (AdoCbl) cofac-
tor (Figure 1c; see the Supporting Information, Figure S1).[8f]
AdoCbl is an active form of cobalamin that is also synthesized
in the mitochondria of eukaryotic cells.[9] In mammals,
cobalamins are required for red blood cell formation, neural
function, as well as protein and DNA synthesis, and no
adverse effects have been associated with excess cobalamin
intake in healthy individuals.[10] These properties prompted us
to explore CBDs in mammalian cells for the green-light-
induced disruption of signaling processes that were induced in
the dark.
We first confirmed that cobalamin supplementation is
well tolerated in human embryonic kidney 293 (HEK293)
cells. After incubation with AdoCbl or cyanocobalamin
(CNCbl, a widely manufactured precursor) at a final concen-
tration of 10 mm for 24 h, we did not observe reduced cell
viability (Figure S2; 10 mm corresponds to a typical concen-
tration for cofactor supplementation[2b,3a]). We next tested
whether CBDs can be expressed robustly and without
cytotoxicity by fusing synthetic gene fragments encoding the
618 bp long CBDs of M. xanthus (MxCBD) and T. thermo-
philus (TtCBD), which had been codon-optimized for
expression in human cells,[2b] to the bright yellow fluorescent
protein mVenus (mV) to quantify domain expression.[11] CBD
levels approached that of the robustly expressing human
FK506 binding protein (FKBP) domain (Figure 1d) with no
measurable cytotoxicity or protein aggregation (Figure 1e
and Figure S3).
We next studied the light-induced dissociation of a CBD
fusion protein complex. Complex formation upon ligand
binding is the functional mechanism underlying receptor
tyrosine kinase (RTK) activation, leading to events such as
mitogen-activated protein kinase/extracellular signal regu-
lated kinase (MAPK/ERK) signaling.[12] To control RTK
interactions, we fused MxCBD and TtCBD to the C-terminus
(where chemical oligomerization domains or fluorescent
proteins had been incorporated beforehand without pertur-
bation of the receptor function) of the intracellular domain
(ICD) of the murine fibroblast growth factor receptor 1
(mFGFR1, a prototypical RTK; Figure 2a).[13] We replaced
the N-terminal ligand binding and transmembrane domains
by a myristoylation (MYR) anchor[11, 13b] so that the receptors
are solely controlled by the CBDs. In addition, a C-terminal
hemagglutinin (HA) epitope was incorporated. Interestingly,
we found that the fusion proteins were expressed more
efficiently in HEK293 cells supplemented with AdoCbl than
in cells supplemented with CNCbl or without supplement
(Figure 2b), suggesting that the cofactor facilitates protein
expression. This was not observed for mV fusion proteins,
likely reflecting a difference in expression yield and stability
of the fluorescent protein and receptor ICD fusions (compare
Figure S4 and Figure 1d for experiments with fluorescent
protein performed with and without supplementation, respec-
tively).
Next, we quantified the capability of mFGFR1-MxCBD
and mFGFR1-TtCBD to regulate the MAPK/ERK signaling
pathway using a luciferase reporter gene assay (Figure 2c).
For both fusion receptors, we observed induction in the dark
that was comparable to that of constitutively dimerized
receptor (mFGFR1-IgG; see the Experimental Section in the
Supporting Information). Induction required AdoCbl supple-
mentation, in line with observations that the cofactor is
required for domain interaction.[8c] Upon green-light illumi-
nation, we observed decreased pathway activity comparable
with that in unsupplemented or untransfected cells, suggest-
ing light-induced dissociation of receptor complexes. While
the two fusion receptors generally behaved similar, we
noticed that blue LED light reduced the activity of the
TtCBD fusion receptor, but not that of mFGFR1-MxCBD, to
Figure 2. a) CBDs were fused to the ICD of mFGFR1 to engineer
receptors that are inactivated by green light. b) Expression of mFGFR1-
MxCBD and mFGFR1-TtCBD in HEK293 cells supplemented with
AdoCbl or CNCbl. c) Activation of the MAPK/ERK pathway (LR= lumi-
nescence ratio) by mFGFR1 fused to CBDs or the Fc domain of IgG1
(IgG) and non-transfected (n.t.) cells in response to red (R;
l=670:5 nm, I=14 mWcm@2), green (G; l=545:5 nm,
I=170 mWcm@2), or blue (B; l=470:5 nm, I=200 mWcm@2) light.
Mean values : SEM for three to twelve independent experiments each
performed in triplicate are given. d,e) Phosphorylation of Erk and
mFGFR1-MxCBD or mFGFR1-TtCBD in response to green light
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a similar extent as green light. Control experiments showed
that receptor dimerization is required for signaling in the dark
(determined using a charge inversion substitution (R195E);
see the Experimental Section for details). Furthermore,
through illumination at different light intensities, the signaling
activity can be tuned to intermediate levels (Figure S5).
Collectively, these results demonstrate that green light
effectively inhibits the activity of mFGFR1-CBD receptors
and that AdoCbl is required for complex formation in the
dark.
We also explored the temporal precision of light-induced
receptor and downstream pathway inactivation (Figure 2d,e).
We confirmed by immunoblotting that the receptors and the
downstream signaling protein Erk are phosphorylated in the
dark in the presence of AdoCbl, with the phosphorylation
decreasing to baseline levels within 5 min of green-light
illumination for Erk and 30 min for mFGFR1. These results
also indicate that dissociated receptors remain phosphory-
lated without downstream signal propagation. We also inves-
tigated the phosphorylation recovery upon cessation of
illumination. When placed in the dark for 60 min after
30 min illumination, the mFGFR1-MxCBD phosphorylation
recovered to 86% of the original value, whereas no recovery
was observed for mFGFR1-TtCBD (Figure 2d,e and Fig-
ure S6a,b). Erk phosphorylation also showed no recovery at
this time point, possibly reflecting the complex behavior of
the signaling pathway.[14] We investigated the molecular
mechanism underlying this difference, which we hypothesized
to reflect the ability of CBDs for cofactor exchange. For
TtCBD, it was shown that the corrin ring of AdoCbl forms
a stable adduct with a histidine residue (H132; in full-length
CarH), preventing the release of bleached cofactor from its
binding pocket.[8f] Indeed, substitution of this residue
(H497A) led to phosphorylation recovery (Figure S7; sub-
stitution of the corresponding glutamate residue in mFGFR1-
MxCBD with a histidine (E499H) diminished activity, pre-
venting detailed analysis). Thus CBDs can be used for
reversible or irreversible optical control of protein complex
dissociation.
To assess the potential of CBDs for optogenetics in
vertebrates, we chose to employ mFGFR1-MxCBD to
manipulate zebrafish (Danio rerio) embryogenesis as FGF is
an important signaling axis during vertebrate development.[15]
We first investigated whether mFGFR1 is functional in
zebrafish. Transient overexpression of the constitutively
active mFGFR1-IgG caused developmental malformations
such as caudalization of the brain and the formation of
a secondary axis, similar to a previously described constitu-
tively active zebrafish FGFR1[15a] (Figure 3a,b). We next
confirmed that injection of AdoCbl and mFGFR1-MxCBD
alone did not negatively impact animal development (Fig-
ure 3c,d). To demonstrate light control over mFGFR1-
MxCBD signaling, we raised animals injected with the
receptor and AdoCbl either in the dark or under green-light
irradiation (l= 545: 5 nm, I= 180 mWcm@2). In the dark,
they showed malformations comparable to those of animals
injected with mFGFR1-IgG, suggesting a similar constitu-
tively active mode of action. On the other hand, embryos
treated with green light did not show abnormalities, demon-
strating that mFGFR1-MxCBD signaling can be turned off
with green light in vivo (Figure 3e, f). These results indicate
that MxCBD is functional in a vertebrate model organism and
that mFGFR1-MxCBD can be used for temporal control to
investigate consequences of aberrant FGF signaling during
periods of development.
Optogenetic methods that induce the formation of protein
complexes in response to blue and red light have matured into
important research tools. Herein, we have shown that CBDs
enable the dissociation of protein complexes upon green-light
irradiation. The activation of mFGFR1-CBDs in human cells
and zebrafish embryos in the dark resulted in constitutively
active signaling and abnormal phenotypes, which could be
prevented with green light. The generation of such signals
with conventional optogenetic methods would require con-
stant illumination with a risk of bleaching, phototoxicity, and
the potential necessity to track the animals. However, we have
now shown that green light can be used to inhibit receptor
activity either reversibly or irreversibly and with potential for
multichromatic experiments. CBDs critically expand the
repertoire of photoreceptor domains in optogenetics, and
will enable new approaches for cell-based and animal studies.
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